Keros Therapeutics/$KROS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Keros Therapeutics
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Ticker
$KROS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
163
ISIN
US4923271013
Website
KROS Metrics
BasicAdvanced
$575M
129.86
$0.11
1.33
-
Price and volume
Market cap
$575M
Beta
1.33
52-week high
$67.89
52-week low
$9.12
Average daily volume
827K
Financial strength
Current ratio
19.287
Quick ratio
18.79
Long term debt to equity
2.238
Total debt to equity
2.526
Management effectiveness
Return on assets (TTM)
-1.01%
Return on equity (TTM)
0.71%
Valuation
Price to earnings (TTM)
129.864
Price to revenue (TTM)
2.548
Price to book
0.79
Price to tangible book (TTM)
0.79
Price to free cash flow (TTM)
12.629
Growth
Revenue change (TTM)
91,657.69%
Earnings per share change (TTM)
-102.13%
3-year revenue growth (CAGR)
120.24%
3-year earnings per share growth (CAGR)
-66.31%
What the Analysts think about KROS
Analyst ratings (Buy, Hold, Sell) for Keros Therapeutics stock.
KROS Financial Performance
Revenues and expenses
KROS Earnings Performance
Company profitability
KROS News
AllArticlesVideos
Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring
GlobeNewsWire·4 days ago
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros' Director Nominees
GlobeNewsWire·6 days ago
Keros Reinforces Commitment to Maximizing Stockholder Value
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Keros Therapeutics stock?
Keros Therapeutics (KROS) has a market cap of $575M as of June 02, 2025.
What is the P/E ratio for Keros Therapeutics stock?
The price to earnings (P/E) ratio for Keros Therapeutics (KROS) stock is 129.86 as of June 02, 2025.
Does Keros Therapeutics stock pay dividends?
No, Keros Therapeutics (KROS) stock does not pay dividends to its shareholders as of June 02, 2025.
When is the next Keros Therapeutics dividend payment date?
Keros Therapeutics (KROS) stock does not pay dividends to its shareholders.
What is the beta indicator for Keros Therapeutics?
Keros Therapeutics (KROS) has a beta rating of 1.33. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.